已收盘 02-06 16:00:00 美东时间
+0.300
+0.87%
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
今日重点评级关注:HC Wainwright & Co.:维持BioCryst Pharma"买入"评级,目标价从30美元升至32美元;TD Cowen:上调Milestone Pharmaceuticals评级至"买入",目标价8美元
2025-12-16 09:36
Citigroup analyst Michael Ward maintains Cooper-Standard Holdings (NYSE:CPS) with a Neutral and raises the price target from $31 to $35.
2025-12-16 05:22
Cooper-Standard Holdings (($CPS)) has held its Q3 earnings call. Read on for th...
2025-11-04 08:21
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Cooper-Standard业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **2025年第三季度:** - 营收:6.955亿美元,同比增长1.5% - 毛利率:12.5%,同比提升140个基点 - 调整后EBITDA:5,330万美元,同比增长超过15.6% - GAAP净亏损:760万美元,较去年同期1,110万美元亏损有所改善 - 调整后净亏损:440万美元(每股0.24美元),较去年同期1,200万美元亏损(每股0.68美元)大幅改善 - 自由现金流:2,700万美元,同比增加超过1,100万美元 - 经营现金流:3,90
2025-11-02 12:01
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gai...
2025-10-31 20:09
Cooper-Standard Holdings (NYSE:CPS) lowers FY2025 sales outlook from $2.700 billion-$2.800 billion to $2.680 billion-$2.720 billion vs $2.767 billion estimate.
2025-10-31 04:32
Cooper-Standard Holdings (NYSE:CPS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $0.11 by 322.22 percent. This is a 64.71 percent increase over losses of $(0.68) per share
2025-10-31 04:32
今日重点评级关注:Maxim Group:维持Rani Therapeutics Hldgs"买入"评级,目标价从5美元升至10美元;韦德布什:维持Corbus Pharmaceuticals"跑赢大市"评级,目标价从31美元升至38美元
2025-10-21 18:13
Stifel analyst Nathan Janes maintains Cooper-Standard Holdings (NYSE:CPS) with a Buy and raises the price target from $39 to $41.
2025-10-20 22:39